Moms’ blood sugar affects fetal heart
Elevated maternal blood sugar when the fetal heart is forming has been linked to a heightened risk for congenital heart defects, according to a new Stanford study.
Drug blocks several mosquito-borne viruses
A new Stanford study details how to shut off proteins in mammalian cells to keep viruses such as Zika, dengue and West Nile from invading.
Multiple food allergies treated safely
Combining an antibody drug, omalizumab, with a procedure to desensitize children to multiple food allergies is safe and effective, according to a new study by Stanford researchers.
Drug for disorder sparks ethical concerns
Medical experts at Stanford and their colleagues at several other universities have raised ethical questions about the way a treatment for spinal muscular atrophy is being used.
Chemotherapy declines for breast cancer
Chemotherapy use for early stage breast cancer declined from 2013 to 2015, possibly due to a preference for less toxic treatments, according to researchers at Stanford and the University of Michigan.
Male health condition linked to new risk
Harnessing the power of big data, Stanford researchers found that enlarged veins on the scrotum are linked with a higher risk of vascular and metabolic disease in men.
Stem cells for fat have circadian clock
New discoveries about the circadian-clock machinery in the precursors to fat cells may explain why shift workers are prone to metabolic diseases, such as diabetes, a Stanford study finds.
Second ‘don’t eat me’ signal found on cancer
CD47 is an important inhibitor of cancer-killing immune cells called macrophages. Now Stanford researchers have identified another, similar way to activate macrophages to destroy cancer cells.
‘Drugs’ from gut bugs
Stanford researchers found that manipulating the gut microbe Clostridium sporogenes changed levels of molecules in the bloodstreams of mice and, in turn, affected their health.
Possible new cell therapy for leukemia
Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22.
Leading in Precision Health
Stanford Medicine is leading the biomedical revolution in precision health, defining and developing the next generation of care that is proactive, predictive and precise.
A Legacy of Innovation
Stanford Medicine's unrivaled atmosphere of breakthrough thinking and interdisciplinary collaboration has fueled a long history of achievements.